Mapping the toll road

Since toll-like receptor agonists stimulate innate immunity, Anadys Pharmaceuticals Inc. thinks they may have uses in many different kinds of infections. The company presented human proof-of-principle data last week showing that its isatoribine TLR7 agonist reduced viral load in patients with HCV by about as much as interferon alpha, with reduced side effects.

At the American Association for

Read the full 574 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE